Navigation Links
Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
Date:3/25/2011

MORRISTOWN, N.J., March 25, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the United States District Court for the District of Delaware has ruled that Watson's generic version of Fentora® (fentanyl buccal tablets C-II) infringes United States Patent No. 6,264,981 (the '981 Patent).  The Company said that it was reviewing the court's decision and would evaluate all available options, including an appeal.

Watson's Abbreviated New Drug Application ("ANDA") for its generic version of Fentora® has been approved by the FDA.  

In 2008, Cephalon sued Watson for patent infringement related to its generic version of Fentora®.  On March 11, 2011, the United States District Court for the District of Delaware ruled that Watson's product does not infringe United States Patent Nos. 6,200,604 and 6,974,590 (the '604 and '590 Patents) and that the '604 and '590 Patents are invalid.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading integrated global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, ; the difficulty of predicting the timing and outcome of any appeal of the pending patent litigation; the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Fentora® is a registered trademark of Cima Labs, Inc., a subsidiary of Cephalon, Inc..

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

CONTACTS:

Investors:
Patty Eisenhaur
Watson Pharmaceuticals, Inc.
(973) 355-8141

Media:
Charlie Mayr
Watson Pharmaceuticals, Inc.
(973) 355-8483


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cephalon Wins FENTORA Patent Suit Against Watson
2. Watson Launches Generic Famvir®
3. Heygood, Orr & Pearson: Los Angeles Court Orders Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit
4. Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
5. Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President
6. Watson to Present at the Barclays 2011 Global Healthcare Conference
7. Watson to Present at the Cowen & Company 31st Annual Healthcare Conference
8. Watson to Present at the 2011 Citi Global Healthcare Conference
9. Watson Fourth Quarter 2010 Net Revenue Increases 21% to $953 Million
10. Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit
11. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2010 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 19, 2017  SARES•REGIS Group leased the first ... at Conejo Spectrum Business Park in ... Biotherapeutics, Inc. , a biopharmaceutical company developing meaningful ... that have been underserved by scientific innovation, with ... cancer, autoimmune and infectious disease. Before ...
(Date:4/18/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 6.35% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College is introducing enhancements ... their careers. Beginning in the fall of 2017, Emmanuel’s program will allow registered nurses ... as 16 months and for as little as $14,528. These changes will enable nurses ...
(Date:4/24/2017)... , ... April 24, 2017 , ... Michael Vick announced ... transforming the quarterback position. The former overall number one pick in the 2001 NFL ... career. He holds the record for the most career rushing yards by a quarterback ...
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a ... new strategies to reduce waste, and support renewable energy. They believe this is a ... nature to find solutions for health issues, and maintain that destroying the environment in ...
(Date:4/24/2017)... Boulder, CO (PRWEB) , ... April 24, 2017 ... ... 2017 American Educational Research Association’s Outstanding Public Communication of Education Research Award. The ... the public, including education communities. It recognizes a scholar who has demonstrated the ...
(Date:4/24/2017)... ... ... Bright Pink , a national non-profit organization focusing on the prevention and early detection of ... is proud to announce Katie Thiede as their new Chief Executive Officer. In January, founder ... of the Board and launched a national search to find a visionary new leader to ...
Breaking Medicine News(10 mins):